TIDMRENE
RNS Number : 3426T
ReNeuron Group plc
11 October 2017
11 October 2017 AIM: RENE
ReNeuron Group plc
Director/PDMR Interest in Shares and Share Options
ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based
global leader in the development of cell-based therapeutics, today
announces that, on 9 October 2017, the following grants made on 11
September 2017 under the Company's Long Term Incentive Plan (LTIP)
were deemed accepted by the relevant Persons Discharging Managerial
Responsibilities (PDMRs). Share option grants made to Directors on
11 September 2017, which were separately announced by RNS on 12
September 2017, were also deemed accepted by those Directors on 9
October 2017. Under the terms of the grants, 9 October 2017 was the
final day by which grantees could decline the option granted to
them on 11 September 2017.
Name Title Date Date Total Percentage
of grant LTIP Number shares of issued
of LTIP share of LTIP over shares
share options share which under
options accepted options options option
granted are
& accepted held
----------------- -------------------- ----------- ----------- ------------ ----------- -----------
Randolph 11 Sept 9 Oct
Corteling Head of Research 17 17 3,000,000 12,604,041 0.40%
----------------- -------------------- ----------- ----------- ------------ ----------- -----------
VP Development
& General
Sharon Manager - 11 Sept 9 Oct
Grimster Wales 17 17 5,750,000 19,658,334 0.62%
----------------- -------------------- ----------- ----------- ------------ ----------- -----------
John Hawkins Financial 11 Sept 9 Oct
(i) Controller 17 17 400,000 1,600,000 0.05%
----------------- -------------------- ----------- ----------- ------------ ----------- -----------
Julian Chief Medical 11 Sept 9 Oct
Howell Officer 17 17 5,566,667 21,474,243 0.68%
----------------- -------------------- ----------- ----------- ------------ ----------- -----------
Head of Regulatory 11 Sept 9 Oct
Shaun Stapleton Affairs 17 17 4,533,333 17,461,363 0.55%
----------------- -------------------- ----------- ----------- ------------ ----------- -----------
Chief Scientific 11 Sept 9 Oct
John Sinden Officer 17 17 2,983,333 21,599,743 0.68%
----------------- -------------------- ----------- ----------- ------------ ----------- -----------
The LTIP awards are share options granted at nominal value and
are subject to a three-year holding period, exercisable from the
third anniversary of the award. The options are exercisable subject
to the achievement of the following performance conditions:
1) When the first patient is administered with a ReNeuron cell
therapy in an eighth clinical trial, one third of the options will
vest.
2) When the sixth clinical trial of a ReNeuron cell therapy
completes, one third of the options will vest.
3) If the Total Shareholder Return (TSR) of the Company meets or
exceeds that of the FTSE AIM Healthcare Index in any given three
year period from the date of grant, one third of the options will
vest.
The notifications set out below are provided in accordance with
the requirements of the EU Market Abuse Regulation and provide
further detail.
(i) The grant to Mr Hawkins was made under the Company's
Employee Share Option Plan and is exercisable subject to
achievement of performance conditions (1) and (2) above, with 50%
of the options vesting in each case.
S
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø , Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan +44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Stephanie Watson
Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
Nplus1 Singer Advisory LLP +44 (0) 20 7496 3000
Mark Taylor (Joint Broker)
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development
company. Based in the UK, its primary objective is the development
of novel cell-based therapies targeting areas of significant unmet
or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop
cell-based therapies for significant disease conditions where the
cells can be readily administered "off-the-shelf" to any eligible
patient without the need for additional immunosuppressive drug
treatments. The Company has therapeutic candidates in clinical
development for disability as a result of stroke, for critical limb
ischaemia and for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential new nanomedicine targeting cancer and as a
potential delivery system for drugs that would otherwise lack
adequate capacity to penetrate to their site of action.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. Further information on ReNeuron and its products can
be found at www.reneuron.com.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Randolph Corteling
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Head of Research
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 3,000,000
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
(Disclosure in relation to share options granted and accepted by
Directors and PDMRs)
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Sharon Grimster
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status VP Development & General Manager
- Wales
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 5,750,000
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name John Hawkins
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Financial Controller
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 400,000
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Julian Howell
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Chief Medical Officer
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 5,566,667
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Shaun Stapleton
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Head of Regulatory Affairs
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 4,533,333
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name John Sinden
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Chief Scientific Officer
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 2,983,333
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Olav Hellebo
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Chief Executive Officer
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 9,766,667
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Michael Hunt
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Chief Financial Officer
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 6,800,000
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name John Berriman
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Non-Executive Chairman
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 500,000
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Simon Cartmell
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Non-Executive Director
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 500,000
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Tim Corn
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Non-Executive Director
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 500,000
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Claudia D'Augusta
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Non-Executive Director
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 500,000
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Chris Evans
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Non-Executive Director
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 500,000
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
---- ----------------------------------------------------------------
a) Name Mike Owen
---- ------------------------ --------------------------------------
2 Reason for the notification
---- ----------------------------------------------------------------
a) Position/status Non-Executive Director
---- ------------------------ --------------------------------------
b) Initial notification Initial notification
/Amendment
---- ------------------------ --------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---- ----------------------------------------------------------------
a) Name ReNeuron Group plc
---- ------------------------ --------------------------------------
b) LEI N/A
---- ------------------------ --------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
---- ----------------------------------------------------------------
a) Description Ordinary Shares 1p
of the financial RENE - GB00B0DZML60
instrument,
type of instrument
Identification
code
---- ------------------------ --------------------------------------
b) Nature of the Grant of share options
transaction
---- ------------------------ --------------------------------------
c) Price(s) and Price(s) Volume(s)
volume(s) --------- ----------
1p 500,000
--------- ----------
---- ------------------------ --------------------------------------
d) Aggregated N/A
information
---- ------------------------ --------------------------------------
e) Date of the Granted 11 September 2017; Deemed
transaction accepted 9 October 2017
---- ------------------------ --------------------------------------
f) Place of the Outside a trading venue
transaction
---- ------------------------ --------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHEAAEFFAPXFFF
(END) Dow Jones Newswires
October 11, 2017 08:31 ET (12:31 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024